Subacute sclerosing panencephalitis

Last updated
Subacute sclerosing panencephalitis
Other namesDawson disease
Bonthius1b.gif
Subacute sclerosing panencephalitis.
Specialty Neurology, Infectious Disease
Symptoms Behavior changes, seizures, spasticity, poor coordination, coma
Usual onset6–15 years after infection with measles
Causes Measles virus
Risk factors Measles infection
Diagnostic method EEG, Serologic testing, brain biopsy
Prevention Measles vaccine
TreatmentSupportive treatment
Medication Intrathecal interferon alpha, intravenous ribavirin, isoprinosine
Prognosis Usually fatal
Frequency2 in 10,000 for all age groups; [1] as high as 1 in 609 for unvaccinated infants under 15 months [2]

Subacute sclerosing panencephalitis (SSPE), also known as Dawson disease, is a rare form of progressive brain inflammation caused by a persistent infection with the measles virus. The condition primarily affects children, teens, and young adults. It has been estimated that about 2 in 10,000 people who get measles will eventually develop SSPE. [1] However, a 2016 study estimated that the rate for unvaccinated infants under 15 months was as high as 1 in 609. [2] [3] No cure for SSPE exists, and the condition is almost always fatal. SSPE should not be confused with acute disseminated encephalomyelitis, which can also be caused by the measles virus, but has a very different timing and course. [4]

Contents

SSPE is caused by some strains of the wild-type (naturally occurring) measles virus, such as the B3 strain [5] , but not by the strains used in measles vaccines. [6] [5]

Signs and symptoms

SSPE is characterized by a history of primary measles infection, followed by a normal, unremarkable recovery. [5] Symptoms of SSPE appear later. [5] On average, the first symptoms appear about 10 years after the initial infection, though this varies significantly, as some people have developed SSPE symptoms as soon as 1 month after infection, and others as long as 27 years later. [5]

After the asymptomatic period, progressive neurological deterioration occurs, characterized by behavior change, intellectual problems, myoclonic seizures, blindness, ataxia, and eventually death. [7] [8]

The very earliest symptoms are small, subtle changes in behavior, such as not paying attention or struggling with schoolwork. [9] By the time family members have become concerned, the disease is at Stage 1, and shows nonspecific symptoms of neurological problems, such as being more irritable than usual, more affectionate than usual, lethargic, or having speech difficulties. [9] Because the symptoms are nonspecific, it this stage it may be obvious to people who know the child well that something is wrong, but unclear what the problem is.

Later symptoms are not subtle. They include myoclonic seizures, epileptic seizures, loss of vision, loss of coordination, and difficulty moving. [9]

Stages of progression

There are multiple staging systems. Symptoms progress through four stages, such as these: [10] [11]

Pathogenesis

SSPE is caused by a latent infection by mutated copies of wild type (naturally occurring) measles virus. [5] A large number of nucleocapsids are produced in the neurons and the glial cells. In these cells the viral genes that encode envelope proteins have restricted expression. [12] As a result, infectious particles like the M protein are not produced, and the virus is able to survive persistently without evoking an immune response. Eventually the infection will lead to SSPE. [13]

When SSPE begins, it demyelinates nerves, causing them to signal unreliably. [9] Later, the brain cortex atrophies, and the ventricular system becomes dilated. [9] Nerve cells are destroyed through phagocytosis. [9] Tauopathies and neurofibrillary tangles develop. [9]

Diagnosis

SSPE may be suspected in any child with symptoms of a progressive (keeps getting worse) neurological disease and who has never been vaccinated against measles. [9]

Typical diagnostic tests include electroencephalography (EEG) to look for evidence of epilepsy or other disturbances to brain waves and a test of the cerebrospinal fluid to look for elevated levels of antibodies against measles and to rule out multiple sclerosis. [9] Magnetic resonance imaging (MRI) of the brain usually looks normal early in the disease. [9]

Treatment

There is no cure. [14] Most treatments are supportive measures, such as anticonvulsants to reduce seizures. [8]

If the diagnosis is made early, oral isoprinosine (Inosiplex) is standard, [9] but it is expensive and only stabilizes or improves symptoms for about 30% of people with SSPE. [5] Less effective medications include intraventricular interferon alfa, amantadine, ribavirin, and others. [5] Immunoglobulin therapy (IVIG) is also used. [9] Isoprinosine is sometimes combined with interferon alfa. [5] [9]

Following onset of stage 2, the disease is invariably fatal.

Prevention

SSPE is a disease for which prevention is the best medicine. [5] [9] SSPE can be prevented by vaccinating children against measles before they become infected. [5] The strain of measles virus in the measles vaccines do not cause SSPE. [5]

Prognosis

Almost everyone who develops SSPE dies as a result of SSPE or secondary complications [5] . Commonly, the person dies within a few months to a few years. [5] Faster deterioration in cases of acute fulminant SSPE can lead to death within 3 months of diagnosis. [15] [16] This faster progression may be called measles inclusion body encephalitis. [9]

Although the prognosis is bleak for SSPE past stage 1, there is a 5% spontaneous remission rate. This may take the form of either a full remission of symptoms that may last many years, or an improvement in condition, giving a longer progression period, or else at least a longer period with the less severe symptoms. [16] [17]

If a remission is achieved, the subsequent relapse is untreatable. [18]

Epidemiology

The number of people who develop SSPE depends on the number of people who get sick with measles. [5] For every 100,000 children or adults who get measles, between 4 and 11 of them will develop SSPE. [5] An outbreak of measles within any community is "inevitably" followed by an uptick in SSPE among the people (usually children) who had been infected with measles. [9]

The chance of developing SSPE is higher for babies (about 1 in 600 infected babies will later develop SSPE) than for those who had measles when they were older. [5] Boys develop SSPE about three times as often as girls. [9]

SSPE is a rare condition, although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine. Eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease, or even the initial infection itself. [19]

History

SSPE was first described by James R. Dawson, Jr. of the Vanderbilt University School of Medicine in 1933. [9]

References

  1. 1 2 Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, Shieh WJ, Rota PA (2005). "Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized". The Journal of Infectious Diseases. 192 (10): 1686–1693. doi: 10.1086/497169 . PMID   16235165.
  2. 1 2 Wendorf, K, Winter, K, Harriman, K, Zipprich, J, Schechter, R, Hacker, J, Preas, C, Cherry JD, Glaser, C (2016). "Subacute Sclerosing Panencephalitis: The Devastating Measles Complication Is More Common Than We Think". Open Forum Infectious Diseases. 3. doi: 10.1093/ofid/ofw194.81 .
  3. ↑ Sun, Lena (October 28, 2016). "New data shows a deadly measles complication is more common than thought". The Washington Post . Retrieved October 28, 2016.
  4. ↑ Fisher DL, Defres S, Solomon T (2015). "Measles-induced encephalitis". QJM. 108 (3): 177–182. doi: 10.1093/qjmed/hcu113 . PMID   24865261.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Samia, Pauline; Oyieke, Katherine; Tunje, Dorcas; Udwadia-Hegde, Anaita; Feemster, Kristen; Oncel, Ibrahim; Anlar, Banu (March 2022). "Options in the Treatment of Subacute Sclerosing Panencephalitis: Implications for Low Resource Areas". Current Treatment Options in Neurology. 24 (3): 99–110. doi:10.1007/s11940-022-00710-x. ISSN   1092-8480. PMC   8933242 . PMID   35340572.
  6. ↑ Jafri, Sidra K; Kumar, Raman; Ibrahim, Shahnaz H (2018-06-26). "Subacute sclerosing panencephalitis – current perspectives". Pediatric Health, Medicine and Therapeutics. 9: 67–71. doi: 10.2147/PHMT.S126293 . ISSN   1179-9927. PMC   6027681 . PMID   29985487.
  7. ↑ "CDC pinkbook". 2019-03-29.
  8. 1 2 "merckmanuals.com".
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Patterson, Marc C. (February 2020). "Neurological Complications of Measles (Rubeola)". Current Neurology and Neuroscience Reports. 20 (2). doi:10.1007/s11910-020-1023-y. ISSN   1528-4042.
  10. ↑ "medline.gov".
  11. ↑ National Institute of Neurological Disorders and Stroke (NINDS) (27 March 2019). "Subacute Sclerosing Panencephalitis Information Page | National Institute of Neurological Disorders and Stroke". ninds.nih.gov. Archived from the original on January 4, 2017. Retrieved 21 November 2021. The initial symptoms of SSPE are subtle and include mild mental deterioration (such as memory loss) and changes in behavior (such as irritability) followed by disturbances in motor function, including uncontrollable involuntary jerking movements of the head, trunk or limbs called myoclonic jerks. Seizures may also occur. Some people may become blind. In advanced stages of the disease, individuals may lose the ability to walk, as their muscles stiffen or spasm. There is progressive deterioration to a comatose state, and then to a persistent vegetative state. Death is usually the result of fever, heart failure, or the brain's inability to continue controlling the autonomic nervous system.
  12. ↑ Jawetz. Melnick & Adelberg's Medical Microbiology. Lange. 2010. p. 586. ISBN   978-0-07-174271-9.
  13. ↑ Carter, M. J.; Willcocks, M. M.; Ter Meulen, V. (1983). "Defective translation of measles virus matrix protein in a subacute sclerosing panencephalitis cell line". Nature. 305 (5930): 153–5. Bibcode:1983Natur.305..153C. doi:10.1038/305153a0. PMC   7094927 . PMID   6888557.
  14. ↑ Rocke, Zoe; Belyayeva, Mariya (2022), "Subacute Sclerosing Panencephalitis", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   32809508 , retrieved 2023-03-10
  15. ↑ Risk WS, Haddad FS (1979). "The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East". Arch Neurol. 56 (10): 610–14. doi:10.1001/archneur.1979.00500460044004. PMID   485888.
  16. 1 2 Garg, R K (1 February 2002). "Subacute sclerosing panencephalitis". Postgraduate Medical Journal. 78 (916): 63–70. doi:10.1136/pmj.78.916.63. PMC   1742261 . PMID   11807185.
  17. ↑
  18. ↑ Gascon, Generoso G. (December 2003). "Randomized Treatment Study of Inosiplex Versus Combined Inosiplex and Intraventricular Interferon-α in Subacute Sclerosing Panencephalitis (SSPE): International Multicenter Study". Journal of Child Neurology. 18 (12): 819–827. doi:10.1177/088307380301801201. ISSN   0883-0738.
  19. ↑ Mubbashir, Zainab; Tharwani, Zoaib Habib; Kambar, Tilyan; Munawar, Sadia; Raphael, Ozem; Siddiqui, Iman; Nadeem, Syeda Ayesha; Amir, Ayesha; Ahmed, Amina; Bin Zafar, Muhammad Daim; Anjum, Muhammad Umair; Hasanain, Muhammad; Malikzai, Abdullah (February 2025). "Subacute Sclerosing Panencephalitis: Impact on Public Health, Current Insights, and Future Perspectives". Brain and Behavior. 15 (2): e70292. doi:10.1002/brb3.70292. ISSN   2162-3279. PMC   11808179 . PMID   39924947.{{cite journal}}: CS1 maint: article number as page number (link)

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.